UY34983A - Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv") y c omposiciones relacionadas - Google Patents
Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv") y c omposiciones relacionadasInfo
- Publication number
- UY34983A UY34983A UY34983A UY34983A UY34983A UY 34983 A UY34983 A UY 34983A UY 34983 A UY34983 A UY 34983A UY 34983 A UY34983 A UY 34983A UY 34983 A UY34983 A UY 34983A
- Authority
- UY
- Uruguay
- Prior art keywords
- hcv
- hepatitis
- replication
- inhibit
- ompositions
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000010076 replication Effects 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 title 1
- 230000000840 anti-viral effect Effects 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 241000711549 Hepacivirus C Species 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
- C07C201/06—Preparation of nitro compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
- C07C205/19—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/26—Polyhydroxylic alcohols containing only six-membered aromatic rings as cyclic part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Compuestos eficaces para inhibir la replicación del virus de la hepatitis C (?HCV?). Esta invención también se relaciona con procesos de elaboración de tales compuestos, con composiciones que compre nden a dichos compuestos y con métodos de uso de dichos para tratar una infección por HCV
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UY34983A UY34983A (es) | 2009-06-11 | 2013-08-21 | Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv") y c omposiciones relacionadas |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18629109P | 2009-06-11 | 2009-06-11 | |
US24283609P | 2009-09-16 | 2009-09-16 | |
US24359609P | 2009-09-18 | 2009-09-18 | |
UY32699A UY32699A (es) | 2009-06-11 | 2010-06-10 | Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv"), procesos, composiciones, y métodos relacionados |
UY34983A UY34983A (es) | 2009-06-11 | 2013-08-21 | Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv") y c omposiciones relacionadas |
Publications (1)
Publication Number | Publication Date |
---|---|
UY34983A true UY34983A (es) | 2014-01-31 |
Family
ID=43066241
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY32699A UY32699A (es) | 2009-06-11 | 2010-06-10 | Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv"), procesos, composiciones, y métodos relacionados |
UY34983A UY34983A (es) | 2009-06-11 | 2013-08-21 | Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv") y c omposiciones relacionadas |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY32699A UY32699A (es) | 2009-06-11 | 2010-06-10 | Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv"), procesos, composiciones, y métodos relacionados |
Country Status (40)
Country | Link |
---|---|
US (5) | US8691938B2 (es) |
EP (5) | EP2337781B1 (es) |
JP (6) | JP5530514B2 (es) |
KR (2) | KR101677481B1 (es) |
CN (4) | CN103819459B (es) |
AR (3) | AR077060A1 (es) |
AU (1) | AU2010258769C1 (es) |
BR (1) | BRPI1004894B8 (es) |
CA (1) | CA2737601C (es) |
CL (2) | CL2011000689A1 (es) |
CO (1) | CO6440538A2 (es) |
CY (2) | CY1114356T1 (es) |
DK (3) | DK2368890T3 (es) |
DO (2) | DOP2011000087A (es) |
EA (3) | EA023570B1 (es) |
EC (3) | ECSP11010937A (es) |
ES (4) | ES2565536T3 (es) |
HK (4) | HK1170739A1 (es) |
HR (3) | HRP20130671T1 (es) |
HU (2) | HUE028825T2 (es) |
IL (4) | IL211792A (es) |
LT (1) | LTC2368890I2 (es) |
LU (1) | LU92668I2 (es) |
MX (2) | MX2011005673A (es) |
MY (1) | MY186633A (es) |
NL (1) | NL300731I1 (es) |
NO (1) | NO2015012I1 (es) |
NZ (1) | NZ591973A (es) |
PE (2) | PE20110679A1 (es) |
PH (1) | PH12015500289A1 (es) |
PL (3) | PL2628481T3 (es) |
PT (2) | PT2368890E (es) |
RS (3) | RS53856B1 (es) |
SG (2) | SG171708A1 (es) |
SI (2) | SI2455376T1 (es) |
TW (4) | TW201519891A (es) |
UA (1) | UA118080C2 (es) |
UY (2) | UY32699A (es) |
WO (1) | WO2010144646A2 (es) |
ZA (3) | ZA201102425B (es) |
Families Citing this family (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012513409A (ja) | 2008-12-23 | 2012-06-14 | アボット・ラボラトリーズ | 抗ウイルス化合物 |
MX2011006333A (es) | 2008-12-23 | 2011-06-27 | Abbott Lab | Compuestos antivirales. |
US8314135B2 (en) | 2009-02-09 | 2012-11-20 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole antivirals |
US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8188132B2 (en) | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
US8242156B2 (en) | 2009-02-17 | 2012-08-14 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8101643B2 (en) | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8673954B2 (en) | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
TWI476190B (zh) * | 2009-03-30 | 2015-03-11 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20110237636A1 (en) * | 2009-03-30 | 2011-09-29 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2419404B1 (en) | 2009-04-15 | 2015-11-04 | AbbVie Inc. | Anti-viral compounds |
CA2761258C (en) | 2009-05-13 | 2015-08-04 | Gilead Sciences, Inc. | Antiviral compounds |
US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8937150B2 (en) * | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
US9394279B2 (en) * | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
CN103819459B (zh) * | 2009-06-11 | 2017-05-17 | 艾伯维巴哈马有限公司 | 抗病毒化合物 |
US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
CA2767887A1 (en) | 2009-07-16 | 2011-01-20 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
EP2473056A4 (en) | 2009-09-04 | 2013-02-13 | Glaxosmithkline Llc | CHEMICAL COMPOUNDS |
US9156818B2 (en) | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8759332B2 (en) | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110137633A1 (en) * | 2009-12-03 | 2011-06-09 | Abbott Laboratories | Anti-viral compounds and methods of identifying the same |
US8653070B2 (en) | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20110152246A1 (en) * | 2009-12-18 | 2011-06-23 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
CA2784748A1 (en) | 2009-12-18 | 2011-06-23 | Idenix Pharmaceuticals, Inc. | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
BR112012018529A2 (pt) | 2010-01-25 | 2016-08-09 | Enanta Pharm Inc | inibidores do vírus de hepatite c, sua composição farmacêutica e seu uso, e método para inibição da replicação de um vírus contendo rna |
US8178531B2 (en) | 2010-02-23 | 2012-05-15 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
US8623814B2 (en) | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
MX2012010252A (es) | 2010-03-04 | 2013-02-01 | Enanta Pharm Inc | Agentes farmaceuticos en combinacion como inhibidores de la replicacion del virus de hepatitis c (hcv). |
MX2012010918A (es) | 2010-03-24 | 2013-01-18 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones por flavivirus. |
EP2555622A4 (en) | 2010-04-09 | 2013-09-18 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
US8778938B2 (en) | 2010-06-04 | 2014-07-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
AU2014200725B2 (en) * | 2010-06-10 | 2016-05-12 | Abbvie Ireland Unlimited Company | Solid compositions |
PE20130395A1 (es) | 2010-06-24 | 2013-04-10 | Gilead Sciences Inc | Pirazolo[1,5-a]pirimidinas para tratamiento antiviral |
WO2012021704A1 (en) | 2010-08-12 | 2012-02-16 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
AU2014203655B2 (en) * | 2010-10-13 | 2016-07-07 | Abbvie Ireland Unlimited Company | Anti-viral compounds |
MY164064A (en) * | 2010-10-13 | 2017-11-15 | Abbvie Bahamas Ltd | Anti-viral compounds |
AU2016238925B2 (en) * | 2010-10-13 | 2018-12-20 | Abbvie Ireland Unlimited Company | Anti-viral compounds |
KR102095698B1 (ko) | 2010-10-29 | 2020-04-01 | 애브비 인코포레이티드 | 아폽토시스―유도제를 포함하는 고체 분산체 |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
WO2012083048A2 (en) * | 2010-12-15 | 2012-06-21 | Abbott Laboratories | Anti-viral compounds |
CA2819894A1 (en) * | 2010-12-16 | 2012-06-21 | Abbvie Inc. | Anti-viral compounds |
US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
EP2709455A4 (en) | 2011-05-18 | 2014-11-05 | Enanta Pharm Inc | PROCESSES FOR THE PREPARATION OF 5-AZASPIRO [2.4] HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES |
US20150126747A1 (en) * | 2011-05-26 | 2015-05-07 | Abbvie Inc. | Anti-viral compounds |
US20150105548A1 (en) * | 2011-05-26 | 2015-04-16 | Abbvie Inc | Anti-viral compounds |
ME03009B (me) | 2011-09-16 | 2018-10-20 | Gilead Pharmasset Llc | Metode za lecenje hcv-a |
AU2013201758B2 (en) * | 2011-10-21 | 2014-11-27 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
AU2015100285B4 (en) * | 2011-10-21 | 2015-06-11 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
SE1450131A1 (sv) | 2011-10-21 | 2014-05-07 | Abbvie Inc | DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
CN104383541A (zh) * | 2011-10-21 | 2015-03-04 | 艾伯维公司 | 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法 |
ES2572355B1 (es) * | 2011-10-21 | 2017-08-24 | Abbvie Inc. | Combinación de aad para uso en el tratamiento del vhc |
AU2015200715A1 (en) * | 2011-10-21 | 2015-03-05 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
EP2602248A1 (en) * | 2011-12-05 | 2013-06-12 | University Of Leicester | Novel pyrrole compounds |
US8946238B2 (en) | 2011-12-22 | 2015-02-03 | Gilead Sciences, Inc. | Pyrazolo[1,5-A]pyrimidines as antiviral agents |
WO2013101552A1 (en) | 2011-12-28 | 2013-07-04 | Abbvie Inc. | Methods for treating hcv |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
CA2857339C (en) * | 2011-12-29 | 2015-11-17 | Abbvie Inc. | Solid compositions comprising an hcv inhibitor |
US9326973B2 (en) * | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
KR102181318B1 (ko) | 2012-04-17 | 2020-11-20 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 치료를 위한 화합물 및 방법 |
WO2014004674A2 (en) | 2012-06-27 | 2014-01-03 | Abbvie Inc. | Methods for treating hcv |
AU2013318309A1 (en) | 2012-09-18 | 2015-04-02 | Abbvie Inc. | Methods for treating hepatitis C |
RU2015114566A (ru) * | 2012-09-18 | 2016-11-10 | Эббви Инк. | Способы лечения гепатита с |
JP2015508418A (ja) | 2013-01-31 | 2015-03-19 | ギリアド ファーマセット エルエルシー | 2種の抗ウイルス化合物のコンビナトリアル製剤 |
CN109908353A (zh) * | 2013-03-14 | 2019-06-21 | 艾伯维公司 | 用于治疗hcv患者的直接作用的抗病毒剂和利巴韦林的组合 |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
WO2015002952A1 (en) | 2013-07-02 | 2015-01-08 | Abbvie Inc. | Methods for treating hcv |
US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
JP2016527232A (ja) | 2013-07-17 | 2016-09-08 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Hcvの治療に使用するためのビフェニル誘導体を含む組み合わせ |
EP4005560A1 (en) | 2013-08-27 | 2022-06-01 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
HRP20220911T1 (hr) | 2013-09-11 | 2022-10-28 | Emory University | Sastav nukleotida i nukleozida i njihova uporaba |
US20150141351A1 (en) * | 2013-11-18 | 2015-05-21 | AbbVie Deutschland GmbH & Co. KG | Solid Pharmaceutical Compositions |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
EP3099295A1 (en) | 2014-01-28 | 2016-12-07 | Abbvie Inc. | Dose adjustment in combination therapy of hepatitis c |
KR20160133004A (ko) | 2014-04-04 | 2016-11-21 | 엑스-알엑스, 인크. | 오토탁신의 치환된 스피로시클릭 억제제 |
CN104030959B (zh) * | 2014-06-24 | 2016-08-24 | 苏州东南药业股份有限公司 | 一种氘代的丙型肝炎病毒抑制剂 |
WO2016040588A1 (en) | 2014-09-11 | 2016-03-17 | Abbvie Inc. | Treatment of hcv by administering four different anti-hcv compounds with food |
CN104402776B (zh) * | 2014-12-05 | 2017-06-13 | 中国石油天然气股份有限公司 | 一种二元醇磺酸酯化合物及其制备方法与应用 |
WO2016134053A1 (en) | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
WO2016134051A1 (en) | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
WO2016134054A1 (en) | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
WO2016134057A1 (en) | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
WO2016134058A1 (en) | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Combinations useful to treat hepatitis c virus |
WO2016134050A1 (en) | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
WO2016134056A1 (en) | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
JO3637B1 (ar) | 2015-04-28 | 2020-08-27 | Janssen Sciences Ireland Uc | مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv |
KR102637828B1 (ko) * | 2015-06-26 | 2024-02-20 | 애브비 인코포레이티드 | Hcv의 치료를 위한 고형 약제학적 조성물 |
US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
JP6743135B2 (ja) | 2015-09-02 | 2020-08-19 | アッヴィ・インコーポレイテッド | 抗ウィルス性テトラヒドロフラン誘導体 |
CN105294828B (zh) * | 2015-11-11 | 2018-09-04 | 苏州明锐医药科技有限公司 | 奥贝他韦的制备方法 |
TW201718608A (zh) * | 2015-11-23 | 2017-06-01 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | 用於抗c型肝炎病毒感染的含矽化合物 |
SG11201808220VA (en) | 2016-03-22 | 2018-10-30 | Merck Sharp & Dohme | Allosteric modulators of nicotinic acetylcholine receptors |
WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
MX2018013178A (es) | 2016-04-28 | 2019-06-24 | Abbvie Inc | Polimorfos cristalinos de ombitasvir. |
RU2659388C1 (ru) | 2017-02-28 | 2018-07-02 | Васильевич Иващенко Александр | Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение |
RU2650610C1 (ru) | 2017-02-28 | 2018-04-16 | Васильевич Иващенко Александр | Противовирусная композиция и способ ее применения |
CN110382487B (zh) * | 2017-03-22 | 2021-04-02 | 正大天晴药业集团股份有限公司 | 用于抗丙型肝炎病毒感染的含硅化合物 |
CN108727345B (zh) * | 2017-04-25 | 2023-06-27 | 广东东阳光药业有限公司 | 一种咪唑环中间体的制备方法 |
GB201706806D0 (en) * | 2017-04-28 | 2017-06-14 | Sentinel Oncology Ltd | Pharmaceutical compounds |
CN107474105B (zh) * | 2017-08-01 | 2021-08-31 | 安徽拜善晟制药有限公司 | 一种原料药奥比他韦的制备方法 |
CN107987083A (zh) * | 2017-11-24 | 2018-05-04 | 江苏亚盛医药开发有限公司 | 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物 |
TW201932470A (zh) | 2017-11-29 | 2019-08-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 具有抗rsv活性之吡唑并嘧啶 |
EA202091835A1 (ru) | 2018-01-31 | 2020-10-20 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Замещенные циклоалкилом пиразолопиримидины, обладающие активностью против rsv |
IL300572A (en) | 2018-02-13 | 2023-04-01 | Gilead Sciences Inc | PD–1/PD–L1 inhibitors |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
ES2957316T3 (es) | 2018-04-23 | 2024-01-17 | Janssen Sciences Ireland Unlimited Co | Compuestos heteroaromáticos que tienen actividad contra VSR |
PE20210642A1 (es) | 2018-07-13 | 2021-03-23 | Gilead Sciences Inc | Inhibidores de pd-1/pd-l1 |
AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
CN115298173A (zh) * | 2020-03-31 | 2022-11-04 | 田边三菱制药株式会社 | 羟基吡咯烷衍生物及其医药用途 |
WO2021236475A1 (en) * | 2020-05-18 | 2021-11-25 | Asinex Corporation | Compounds that inhibit asparagine synthetase and their methods of use |
WO2022246109A1 (en) | 2021-05-21 | 2022-11-24 | Gilead Sciences, Inc. | Pentacyclic derivatives as zika virus inhibitors |
CN115594591A (zh) * | 2021-06-28 | 2023-01-13 | 凯特立斯(深圳)科技有限公司(Cn) | 一种催化不对称氢化制备哌仑他韦中间体的方法 |
CN114656389B (zh) * | 2022-04-27 | 2023-12-15 | 河南大学 | 一种1-苯基吡咯烷的合成方法 |
Family Cites Families (201)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE75755C (de) | 1894-06-14 | DAHL & COMP, in Barmen | Verfahren zur Darstellung von aromatisch substituirten Amidodinaphtylmethanen. | |
US3225061A (en) * | 1962-10-17 | 1965-12-21 | Nat Distillers Chem Corp | Derivatives of 2,5-diarylpyrrole |
JPS62195307A (ja) * | 1986-02-24 | 1987-08-28 | Kumiai Chem Ind Co Ltd | 農園芸用殺菌剤 |
EP0701446A4 (en) | 1993-05-24 | 1997-04-23 | Smithkline Beecham Corp | HEMOREGULATORS PEPTIDES |
US5683999A (en) * | 1995-03-17 | 1997-11-04 | The Dupont Merck Pharmaceutical Company | Cyclic urea HIV protease inhibitors |
SI9500173B (sl) | 1995-05-19 | 2002-02-28 | Lek, | Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo |
US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
JPH09255949A (ja) * | 1996-03-21 | 1997-09-30 | Idemitsu Kosan Co Ltd | 有機エレクトロルミネッセンス素子 |
US5935982A (en) * | 1997-02-28 | 1999-08-10 | The University Of North Carolina At Chapel Hill | Methods of treating retroviral infection and compounds useful therefor |
US6235493B1 (en) * | 1997-08-06 | 2001-05-22 | The Regents Of The University Of California | Amino acid substituted-cresyl violet, synthetic fluorogenic substrates for the analysis of agents in individual in vivo cells or tissue |
US6919366B2 (en) * | 1998-05-22 | 2005-07-19 | Avanir Pharmaceuticals | Benzimidazole derivatives as modulators of IgE |
US6911462B2 (en) * | 1998-05-22 | 2005-06-28 | Avanir Pharmaceuticals | Benzimidazole compounds for regulating IgE |
US6369091B1 (en) * | 1998-05-22 | 2002-04-09 | Avanir Pharmaceuticals | Benzimidazole analogs as down-regulators of IgE |
ATE292465T1 (de) | 1998-05-22 | 2005-04-15 | Avanir Pharmaceuticals | Benzimidazol-derivate als ige-modulatoren |
KR100336090B1 (ko) | 1998-06-27 | 2002-05-27 | 윤승원 | 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제 |
US6387885B1 (en) | 1998-08-26 | 2002-05-14 | Abbott Laboratories | 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists |
JP3968933B2 (ja) * | 1998-12-25 | 2007-08-29 | コニカミノルタホールディングス株式会社 | エレクトロルミネッセンス素子 |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
DE19913692A1 (de) | 1999-03-25 | 2000-09-28 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
US6610688B2 (en) | 1999-12-21 | 2003-08-26 | Sugen, Inc. | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
CA2405521C (en) * | 2000-04-05 | 2010-06-29 | Schering Corporation | Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties |
DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
US7065453B1 (en) | 2000-06-15 | 2006-06-20 | Accelrys Software, Inc. | Molecular docking technique for screening of combinatorial libraries |
ES2281434T3 (es) | 2000-08-14 | 2007-10-01 | Ortho-Mcneil Pharmaceutical, Inc. | Pirazoles sustituidos. |
US6388093B1 (en) | 2001-01-05 | 2002-05-14 | Sun Chemical Corporation | Syntheses for preparing 1,4-diketopyrrolo [3,4-c]pyrroles |
CN100509797C (zh) | 2001-06-11 | 2009-07-08 | 病毒化学医药公司 | 用作黄病毒感染抗病毒剂的噻吩衍生物 |
EP2335700A1 (en) * | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
RU2286343C2 (ru) | 2001-08-10 | 2006-10-27 | Орто-Макнейл Фармасьютикал, Инк. | Замещенные пиразолы |
AU2003216274A1 (en) * | 2002-02-11 | 2003-09-04 | Neurocrine Biosciences, Inc. | Pyrrole derivatives as ligands of melanocortin receptors |
TW200304820A (en) * | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
JP3925265B2 (ja) * | 2002-03-25 | 2007-06-06 | コニカミノルタホールディングス株式会社 | 有機エレクトロルミネッセンス素子及びそれを用いた表示装置 |
MXPA04012642A (es) | 2002-06-14 | 2005-03-23 | Merck & Co Inc | Inhibidores de la cinesina mitotica. |
WO2004005283A1 (en) | 2002-07-09 | 2004-01-15 | Vertex Pharmaceuticals Incorporated | Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities |
KR100482276B1 (ko) * | 2002-08-12 | 2005-04-13 | 한국과학기술연구원 | 피롤계 화합물, 그 중합체 및 이들을 이용한 el 소자 |
US20050069522A1 (en) | 2002-08-12 | 2005-03-31 | Richard Colonno | Combination pharmaceutical agents as inhibitors of HCV replication |
GB0229518D0 (en) | 2002-12-19 | 2003-01-22 | Astrazeneca Ab | Chemical compounds |
TW200508224A (en) | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
US7544192B2 (en) * | 2003-03-14 | 2009-06-09 | Sinexus, Inc. | Sinus delivery of sustained release therapeutics |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
RU2006118359A (ru) * | 2003-10-27 | 2007-12-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Комбинации для лечения вирусного гепатита с (hcv) |
DK1718608T3 (da) * | 2004-02-20 | 2013-10-14 | Boehringer Ingelheim Int | Virale polymeraseinhibitorer |
BRPI0401908A (pt) | 2004-06-04 | 2006-01-17 | Univ Rio De Janeiro | Compostos inibidores de serina protease, processo de obtenção e uso para tratamento de flaviviroses |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
JP5014129B2 (ja) | 2004-07-27 | 2012-08-29 | ギリアード サイエンシーズ, インコーポレイテッド | イミダゾ[4,5−d]ピリミジン、それらの使用および調製方法 |
AU2005272619A1 (en) | 2004-08-13 | 2006-02-23 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (SIP) receptor activity |
TW200633718A (en) * | 2004-12-16 | 2006-10-01 | Applied Research Systems | Treatment of hepatitis c in the asian population |
EP1844035A1 (en) | 2005-02-01 | 2007-10-17 | Wyeth | Amino-pyridines as inhibitors of beta-secretase |
BRPI0606902A2 (pt) | 2005-02-14 | 2009-07-28 | Wyeth Corp | composto; método para o tratamento de uma doença ou distúrbio associado a atividade excessiva de bace em um paciente que dele necessite; método para modular a atividade de bace; composição farmacêutica |
US7894996B2 (en) | 2005-02-28 | 2011-02-22 | The Rockefeller University | Structure of the hepatitis C NS5A protein |
US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
AU2006261132A1 (en) * | 2005-06-24 | 2006-12-28 | Genelabs Technologies, Inc. | Heteroaryl derivatives for treating viruses |
US7541359B2 (en) | 2005-06-30 | 2009-06-02 | Janssen Pharmaceutica N.V. | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase |
JP2009501217A (ja) | 2005-07-15 | 2009-01-15 | アストラゼネカ アクチボラグ | 治療薬 |
RU2008128452A (ru) | 2005-12-12 | 2010-01-20 | Дженелабс Текнолоджис, Инк. (Us) | Соединения n-(6-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения |
RU2008128453A (ru) | 2005-12-12 | 2010-01-20 | Дженелабс Текнолоджис, Инк. (Us) | Соединение n-(5-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения |
JP2009521479A (ja) | 2005-12-21 | 2009-06-04 | アボット・ラボラトリーズ | 抗ウイルス化合物 |
ES2395386T3 (es) | 2005-12-21 | 2013-02-12 | Abbott Laboratories | Compuestos antivirales |
US7763731B2 (en) * | 2005-12-21 | 2010-07-27 | Abbott Laboratories | Anti-viral compounds |
CA2634699A1 (en) | 2005-12-21 | 2007-06-28 | Decode Genetics Ehf | N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation |
WO2007082554A1 (en) | 2006-01-23 | 2007-07-26 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Modulators of hcv replication |
BRPI0711591A2 (pt) | 2006-05-16 | 2011-11-16 | Aegera Therapeutics Inc | composto de ligação de domìnio bir da iap |
JP2007320925A (ja) * | 2006-06-02 | 2007-12-13 | Mitsubishi Chemicals Corp | トリアリールアミン系化合物並びにそれを用いた電子写真感光体及び画像形成装置 |
EA015127B1 (ru) | 2006-06-08 | 2011-06-30 | Эли Лилли Энд Компани | Антагонисты мсн-рецепторов |
BRPI0713025A2 (pt) | 2006-06-16 | 2012-04-17 | Syngenta Participations Ag | compostos derivados de etenila carboxamida úteis como microbiocidas, método de controle ou prevenção de infestação de plantas úteis por microorganismo fitopatogênicos e composição para controle e prevenção dos referidos microorganismos |
WO2008014236A1 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
US20100143499A1 (en) * | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
US20100158862A1 (en) * | 2006-08-11 | 2010-06-24 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US7745636B2 (en) * | 2006-08-11 | 2010-06-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7759495B2 (en) * | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2097405A2 (en) * | 2006-11-21 | 2009-09-09 | Smithkline Beecham Corporation | Anti-viral compounds |
WO2008064218A2 (en) | 2006-11-21 | 2008-05-29 | Smithkline Beecham Corporation | Amido anti-viral compounds |
WO2008074450A2 (en) | 2006-12-20 | 2008-06-26 | Nicox S.A. | Non-peptidic renin inhibitors nitroderivatives |
US8236950B2 (en) | 2006-12-20 | 2012-08-07 | Abbott Laboratories | Anti-viral compounds |
NZ580313A (en) | 2007-04-12 | 2011-11-25 | Joyant Pharmaceuticals Inc | Smac mimetic dimers and trimers useful as anti-cancer agents |
CN110724124A (zh) * | 2007-05-17 | 2020-01-24 | 株式会社半导体能源研究所 | 三唑衍生物 |
US7741347B2 (en) * | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2009003009A1 (en) | 2007-06-26 | 2008-12-31 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolidine as anti-infectives |
JP2010535711A (ja) | 2007-08-03 | 2010-11-25 | シェーリング コーポレイション | 複素環式置換ピペラジンを用いる、cxcr3媒介性疾患の処置方法 |
US7728027B2 (en) * | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
US8629171B2 (en) | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
GB0801199D0 (en) | 2008-01-23 | 2008-02-27 | Acal Energy Ltd | Fuel cells |
JP5581219B2 (ja) | 2008-01-25 | 2014-08-27 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | チオフェンおよびホスファチジルイノシトール3−キナーゼ(pi3k)阻害薬としてのその使用 |
JP2011511841A (ja) | 2008-02-12 | 2011-04-14 | ブリストル−マイヤーズ スクイブ カンパニー | C型肝炎ウイルス阻害剤 |
EP2250163B1 (en) | 2008-02-12 | 2012-03-28 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US8147818B2 (en) * | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7704992B2 (en) * | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
BRPI0822323A2 (pt) | 2008-02-13 | 2015-06-16 | Bristol Myers Squibb Co | Imidazolil bifenil imidazóis como inibidores do vírus da hepatite c |
EP2444070A1 (en) | 2008-02-28 | 2012-04-25 | Abbott Laboratories | Tablets |
JP2009246097A (ja) * | 2008-03-31 | 2009-10-22 | Konica Minolta Holdings Inc | 有機エレクトロルミネッセンス素子、表示装置、及び照明装置 |
WO2009136290A1 (en) | 2008-05-05 | 2009-11-12 | Aegera Therapeutics, Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
WO2009143361A1 (en) | 2008-05-22 | 2009-11-26 | Smithkline Beecham Corporation | Amido anti-viral compounds |
WO2009155709A1 (en) | 2008-06-27 | 2009-12-30 | Aegera Therapeutics Inc. | Bridged secondary amines and use thereof as iap bir domain binding compounds |
ES2392611T3 (es) * | 2008-07-22 | 2012-12-12 | Merck Sharp & Dohme Corp. | Compuestos de quinoxalina macrocíclica como inhibidores de la proteasa NS3 del VHC |
CA2730448A1 (en) | 2008-08-02 | 2010-02-11 | Genentech, Inc. | Inhibitors of iap |
WO2010015090A1 (en) | 2008-08-07 | 2010-02-11 | Aegera Therapeutics Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
US7906655B2 (en) * | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8383094B2 (en) * | 2008-10-01 | 2013-02-26 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2010059858A1 (en) | 2008-11-19 | 2010-05-27 | Duke University | Manassantin compounds and methods of making and using same |
JP2010126571A (ja) | 2008-11-26 | 2010-06-10 | Toyo Ink Mfg Co Ltd | 有機エレクトロルミネッセンス素子材料および有機エレクトロルミネッセンス素子 |
US8729077B2 (en) | 2008-11-28 | 2014-05-20 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
NZ593806A (en) | 2008-12-03 | 2014-04-30 | Presidio Pharmaceuticals Inc | Inhibitors of hcv ns5a |
CN104163816A (zh) | 2008-12-03 | 2014-11-26 | 普雷西迪奥制药公司 | Hcv ns5a的抑制剂 |
JP2012513409A (ja) | 2008-12-23 | 2012-06-14 | アボット・ラボラトリーズ | 抗ウイルス化合物 |
MX2011006333A (es) * | 2008-12-23 | 2011-06-27 | Abbott Lab | Compuestos antivirales. |
US8314135B2 (en) * | 2009-02-09 | 2012-11-20 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole antivirals |
EP2393359A4 (en) | 2009-02-09 | 2012-10-03 | Enanta Pharm Inc | COMPOUND DIBENZIMIDAZOLE DERIVATIVES |
WO2010096462A1 (en) | 2009-02-17 | 2010-08-26 | Enanta Pharmaceuticals, Inc | Linked diimidazole derivatives |
US8637561B2 (en) * | 2009-02-17 | 2014-01-28 | Enanta Pharmaceuticals, Inc. | Linked diimidazole derivatives |
US8394968B2 (en) * | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TWI438200B (zh) * | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
US8420686B2 (en) * | 2009-02-17 | 2013-04-16 | Enanta Pharmaceuticals, Inc. | Linked diimidazole antivirals |
US8242156B2 (en) * | 2009-02-17 | 2012-08-14 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
US8188132B2 (en) * | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
WO2010096777A1 (en) | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
UY32462A (es) * | 2009-02-23 | 2010-09-30 | Arrow Therapeutics Ltd | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 |
KR20130130875A (ko) | 2009-02-27 | 2013-12-02 | 이난타 파마슈티칼스, 인코포레이티드 | C형 간염 바이러스 억제제 |
US8101643B2 (en) * | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8426458B2 (en) * | 2009-02-27 | 2013-04-23 | Enanta Pharmaceuticals, Inc. | Hepatitis C Virus inhibitors |
US8673954B2 (en) | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8507522B2 (en) * | 2009-03-06 | 2013-08-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
CN102427729B (zh) | 2009-03-27 | 2014-09-03 | 默沙东公司 | 丙型肝炎病毒复制的抑制剂 |
WO2010111673A1 (en) | 2009-03-27 | 2010-09-30 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic hcv inhibitors |
BRPI1012282A2 (pt) | 2009-03-27 | 2015-09-22 | Presidio Pharmaceuticals Inc | inibidores de anel fundidos da hepatite c. |
US20110237636A1 (en) * | 2009-03-30 | 2011-09-29 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
TWI476190B (zh) | 2009-03-30 | 2015-03-11 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
KR20120022879A (ko) | 2009-04-08 | 2012-03-12 | 바스프 에스이 | 피롤로피롤 유도체, 그의 제조법 및 반도체로서의 용도 |
TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2419404B1 (en) * | 2009-04-15 | 2015-11-04 | AbbVie Inc. | Anti-viral compounds |
US8436036B2 (en) | 2009-04-24 | 2013-05-07 | Janssen R&D Ireland | Diaryl ethers |
WO2010132538A1 (en) | 2009-05-12 | 2010-11-18 | Schering Corporation | Fused tricyclic aryl compounds useful for the treatment of viral diseases |
CA2761258C (en) * | 2009-05-13 | 2015-08-04 | Gilead Sciences, Inc. | Antiviral compounds |
US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
JP2012528194A (ja) | 2009-05-29 | 2012-11-12 | メルク・シャープ・アンド・ドーム・コーポレーション | C型肝炎などの疾患を処置するための3つの整列型アリール部分で構成された抗菌性化合物 |
WO2010138791A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
CN103819459B (zh) | 2009-06-11 | 2017-05-17 | 艾伯维巴哈马有限公司 | 抗病毒化合物 |
US8937150B2 (en) * | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
US8221737B2 (en) * | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
WO2010148006A1 (en) | 2009-06-16 | 2010-12-23 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
US8609648B2 (en) * | 2009-07-02 | 2013-12-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
WO2011004276A1 (en) * | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
CA2767887A1 (en) | 2009-07-16 | 2011-01-20 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
EP2462135A1 (en) | 2009-08-07 | 2012-06-13 | Janssen R&D Ireland | Bis-benzimidazole derivatives as hepatitis c virus inhibitors |
AU2010291215A1 (en) | 2009-09-03 | 2012-02-23 | Janssen Sciences Ireland Uc | Bis-benzimidazole derivatives |
EP2473056A4 (en) | 2009-09-04 | 2013-02-13 | Glaxosmithkline Llc | CHEMICAL COMPOUNDS |
US8927709B2 (en) * | 2009-09-11 | 2015-01-06 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8815928B2 (en) * | 2009-09-11 | 2014-08-26 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US9156818B2 (en) * | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8703938B2 (en) * | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8759332B2 (en) * | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8822700B2 (en) * | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
EP2475254A4 (en) | 2009-09-11 | 2013-05-22 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
WO2011050146A1 (en) | 2009-10-23 | 2011-04-28 | Glaxosmithkline Llc | Chemical compounds |
UA108211C2 (uk) | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110281910A1 (en) * | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20120276047A1 (en) | 2009-11-25 | 2012-11-01 | Rosenblum Stuart B | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
CA2781140C (en) * | 2009-12-04 | 2017-10-24 | National Health Research Institutes | Proline derivatives for use to treat hepatitis c infection |
US8653070B2 (en) * | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2784748A1 (en) * | 2009-12-18 | 2011-06-23 | Idenix Pharmaceuticals, Inc. | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
US20110152246A1 (en) * | 2009-12-18 | 2011-06-23 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
EP2516430B1 (en) | 2009-12-22 | 2014-11-05 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
MX2012007420A (es) | 2009-12-24 | 2012-07-23 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones de flavivirus. |
US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2011091446A1 (en) | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Chemical compounds |
BR112012018529A2 (pt) | 2010-01-25 | 2016-08-09 | Enanta Pharm Inc | inibidores do vírus de hepatite c, sua composição farmacêutica e seu uso, e método para inibição da replicação de um vírus contendo rna |
EP2528926A4 (en) | 2010-01-28 | 2013-06-19 | Boehringer Ingelheim Int | HEPATITIS C INHIBITOR COMPOUNDS |
US8178531B2 (en) * | 2010-02-23 | 2012-05-15 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
MX2012010252A (es) * | 2010-03-04 | 2013-02-01 | Enanta Pharm Inc | Agentes farmaceuticos en combinacion como inhibidores de la replicacion del virus de hepatitis c (hcv). |
AU2011224698A1 (en) * | 2010-03-09 | 2012-11-01 | Merck Sharp & Dohme Corp. | Fused Tricyclic Silyl Compounds and methods of use thereof for the treatment of viral diseases |
EP2550262A1 (en) | 2010-03-24 | 2013-01-30 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
EP2550268A1 (en) | 2010-03-24 | 2013-01-30 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
MX2012010918A (es) | 2010-03-24 | 2013-01-18 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones por flavivirus. |
AU2011232348A1 (en) | 2010-03-24 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of Flavivirus infections |
EP2555622A4 (en) | 2010-04-09 | 2013-09-18 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
US20110312996A1 (en) | 2010-05-17 | 2011-12-22 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
EP2575475A4 (en) | 2010-05-28 | 2013-11-27 | Presidio Pharmaceuticals Inc | HCV NS5A INHIBITORS |
US8778938B2 (en) * | 2010-06-04 | 2014-07-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
CA2802067A1 (en) | 2010-06-09 | 2011-12-15 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a protein |
NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
WO2012040389A2 (en) | 2010-09-22 | 2012-03-29 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic hcv inhibitors |
JP5619289B2 (ja) | 2010-09-24 | 2014-11-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
CN102420414A (zh) * | 2010-09-27 | 2012-04-18 | 通领科技集团有限公司 | 高灵敏度泄漏电流检测断路器 |
US20130280214A1 (en) | 2010-09-29 | 2013-10-24 | Merck Sharp & Dohme Corp. | Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases |
KR20140001879A (ko) | 2010-09-29 | 2014-01-07 | 머크 샤프 앤드 돔 코포레이션 | C형 간염 바이러스 감염을 치료하기 위한 테트라시클릭 인돌 유도체 |
EP2621279B1 (en) | 2010-09-29 | 2018-04-04 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
WO2012040924A1 (en) | 2010-09-29 | 2012-04-05 | Merck Sharp & Dohme Corp. | Fused tetracyclic heterocycle compounds and methods of use thereof for treatment of viral diseases |
WO2012040923A1 (en) | 2010-09-29 | 2012-04-05 | Merck Sharp & Dohme Corp. | Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases |
EP2621932A4 (en) | 2010-09-29 | 2014-03-26 | Merck Sharp & Dohme | TETRACYCLIC HETEROCYCLUS COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS |
ES2548286T3 (es) | 2010-11-04 | 2015-10-15 | Theravance Biopharma R&D Ip, Llc | Nuevos inhibidores del virus de la hepatitis C |
KR20200140924A (ko) | 2010-11-17 | 2020-12-16 | 길리애드 파마셋 엘엘씨 | 항바이러스 화합물 |
RU2452735C1 (ru) | 2010-11-30 | 2012-06-10 | Александр Васильевич Иващенко | Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения |
WO2012087976A2 (en) | 2010-12-21 | 2012-06-28 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
-
2010
- 2010-06-10 CN CN201410012469.7A patent/CN103819459B/zh not_active Expired - Fee Related
- 2010-06-10 BR BRPI1004894A patent/BRPI1004894B8/pt active IP Right Grant
- 2010-06-10 WO PCT/US2010/038077 patent/WO2010144646A2/en active Application Filing
- 2010-06-10 EP EP20100724656 patent/EP2337781B1/en active Active
- 2010-06-10 CN CN201310683080.0A patent/CN103819537A/zh active Pending
- 2010-06-10 JP JP2012515122A patent/JP5530514B2/ja active Active
- 2010-06-10 TW TW104106421A patent/TW201519891A/zh unknown
- 2010-06-10 TW TW102112194A patent/TWI469780B/zh active
- 2010-06-10 ES ES13167828.6T patent/ES2565536T3/es active Active
- 2010-06-10 HU HUE13167828A patent/HUE028825T2/en unknown
- 2010-06-10 US US12/813,301 patent/US8691938B2/en active Active
- 2010-06-10 AU AU2010258769A patent/AU2010258769C1/en active Active
- 2010-06-10 UA UAA201307357A patent/UA118080C2/uk unknown
- 2010-06-10 DK DK11160830T patent/DK2368890T3/da active
- 2010-06-10 TW TW102117266A patent/TWI486159B/zh active
- 2010-06-10 EP EP20110160830 patent/EP2368890B9/en active Active
- 2010-06-10 PE PE2011000800A patent/PE20110679A1/es active IP Right Grant
- 2010-06-10 EA EA201300495A patent/EA023570B1/ru not_active IP Right Cessation
- 2010-06-10 KR KR1020147005631A patent/KR101677481B1/ko active IP Right Grant
- 2010-06-10 KR KR1020117007715A patent/KR101452916B1/ko active Protection Beyond IP Right Term
- 2010-06-10 EA EA201400115A patent/EA026848B1/ru unknown
- 2010-06-10 EA EA201170401A patent/EA020031B1/ru not_active IP Right Cessation
- 2010-06-10 MY MYPI2013002542A patent/MY186633A/en unknown
- 2010-06-10 PE PE2013001987A patent/PE20141083A1/es active IP Right Grant
- 2010-06-10 PT PT11160830T patent/PT2368890E/pt unknown
- 2010-06-10 CN CN2010800034652A patent/CN102333772B/zh active Active
- 2010-06-10 DK DK12155991T patent/DK2455376T3/en active
- 2010-06-10 TW TW99119001A patent/TWI402070B/zh not_active IP Right Cessation
- 2010-06-10 RS RS20150123A patent/RS53856B1/en unknown
- 2010-06-10 ES ES10724656.3T patent/ES2511440T3/es active Active
- 2010-06-10 CA CA2737601A patent/CA2737601C/en active Active
- 2010-06-10 SI SI201030870T patent/SI2455376T1/sl unknown
- 2010-06-10 ES ES11160830T patent/ES2414934T3/es active Active
- 2010-06-10 PL PL13167828T patent/PL2628481T3/pl unknown
- 2010-06-10 UY UY32699A patent/UY32699A/es active IP Right Grant
- 2010-06-10 EP EP20120155991 patent/EP2455376B1/en active Active
- 2010-06-10 SG SG2011023421A patent/SG171708A1/en unknown
- 2010-06-10 CN CN201310069132.5A patent/CN103172620B/zh active Active
- 2010-06-10 EP EP14190636.2A patent/EP2853531A3/en not_active Withdrawn
- 2010-06-10 RS RSP20130301 patent/RS52854B/en unknown
- 2010-06-10 ES ES12155991.8T patent/ES2526908T3/es active Active
- 2010-06-10 PT PT121559918T patent/PT2455376E/pt unknown
- 2010-06-10 SI SI201031187A patent/SI2628481T1/sl unknown
- 2010-06-10 PL PL11160830T patent/PL2368890T3/pl unknown
- 2010-06-10 MX MX2011005673A patent/MX2011005673A/es active IP Right Grant
- 2010-06-10 RS RS20160359A patent/RS54790B1/sr unknown
- 2010-06-10 DK DK13167828.6T patent/DK2628481T3/en active
- 2010-06-10 SG SG10201702522UA patent/SG10201702522UA/en unknown
- 2010-06-10 NZ NZ59197310A patent/NZ591973A/xx unknown
- 2010-06-10 AR ARP100102058 patent/AR077060A1/es active IP Right Grant
- 2010-06-10 EP EP13167828.6A patent/EP2628481B1/en active Active
- 2010-06-10 PL PL12155991T patent/PL2455376T3/pl unknown
- 2010-10-13 US US12/903,822 patent/US20110092415A1/en not_active Abandoned
- 2010-12-09 US US12/964,027 patent/US8921514B2/en not_active Expired - Fee Related
-
2011
- 2011-03-17 IL IL211792A patent/IL211792A/en active IP Right Grant
- 2011-03-29 DO DO2011000087A patent/DOP2011000087A/es unknown
- 2011-03-29 CL CL2011000689A patent/CL2011000689A1/es unknown
- 2011-03-30 EC ECSP11010937 patent/ECSP11010937A/es unknown
- 2011-03-30 CO CO11038996A patent/CO6440538A2/es active IP Right Grant
- 2011-03-31 ZA ZA2011/02425A patent/ZA201102425B/en unknown
- 2011-05-27 MX MX2015002738A patent/MX339989B/es unknown
- 2011-08-05 HK HK12111637.2A patent/HK1170739A1/xx unknown
- 2011-08-05 HK HK13114243.1A patent/HK1186415A1/zh not_active IP Right Cessation
- 2011-08-05 HK HK12101903A patent/HK1161245A1/xx unknown
- 2011-08-05 HK HK11108209A patent/HK1152620A1/xx not_active IP Right Cessation
-
2012
- 2012-05-14 ZA ZA2012/03502A patent/ZA201203502B/en unknown
- 2012-05-14 ZA ZA2012/03503A patent/ZA201203503B/en unknown
-
2013
- 2013-06-26 CY CY20131100518T patent/CY1114356T1/el unknown
- 2013-07-16 HR HRP20130671 patent/HRP20130671T1/hr unknown
- 2013-08-07 CL CL2013002299A patent/CL2013002299A1/es unknown
- 2013-08-13 DO DO2013000185A patent/DOP2013000185A/es unknown
- 2013-08-21 UY UY34983A patent/UY34983A/es not_active Application Discontinuation
- 2013-09-10 AR ARP130103220A patent/AR092505A2/es not_active Application Discontinuation
- 2013-09-20 EC ECSP13010937 patent/ECSP13010937A/es unknown
- 2013-11-01 JP JP2013228032A patent/JP5911838B2/ja active Active
- 2013-11-04 IL IL229248A patent/IL229248A/en active IP Right Grant
-
2014
- 2014-02-14 US US14/180,886 patent/US9006387B2/en active Active
- 2014-02-17 AR ARP140100499A patent/AR094816A2/es unknown
- 2014-04-17 JP JP2014085271A patent/JP5922699B2/ja active Active
- 2014-07-29 IL IL233857A patent/IL233857A/en not_active IP Right Cessation
- 2014-09-22 IL IL234781A patent/IL234781A/en not_active IP Right Cessation
-
2015
- 2015-01-08 HR HRP20150017TT patent/HRP20150017T1/hr unknown
- 2015-02-09 PH PH12015500289A patent/PH12015500289A1/en unknown
- 2015-02-25 LU LU92668C patent/LU92668I2/xx unknown
- 2015-03-04 LT LTPA2015012C patent/LTC2368890I2/lt unknown
- 2015-03-26 CY CY2015012C patent/CY2015012I1/el unknown
- 2015-04-08 NL NL300731C patent/NL300731I1/nl unknown
- 2015-04-10 US US14/683,910 patent/US20150218194A1/en not_active Abandoned
- 2015-04-15 HU HUS1500019C patent/HUS1500019I1/hu unknown
- 2015-04-22 NO NO2015012C patent/NO2015012I1/no not_active IP Right Cessation
-
2016
- 2016-01-14 JP JP2016005394A patent/JP6159830B2/ja active Active
- 2016-04-19 HR HRP20160408TT patent/HRP20160408T1/hr unknown
-
2017
- 2017-06-09 JP JP2017114480A patent/JP6559736B2/ja active Active
- 2017-09-29 EC ECIEPI201764986A patent/ECSP17064986A/es unknown
-
2019
- 2019-07-18 JP JP2019132715A patent/JP2019194254A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY34983A (es) | Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv") y c omposiciones relacionadas | |
CO6761348A2 (es) | Compuestos antivirales | |
CL2012000573A1 (es) | Compuestos derivados de bifenil-pirrolidinil-imidazol; composicion farmaceutica que los comprende; su uso en el tratamiento de una infeccion viral por hcv. | |
GT200900097A (es) | Inhibidores de la proteasa ns3 del hcv. | |
CL2012001176A1 (es) | Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv. | |
CL2010001634A1 (es) | Compuestos derivados de nucleosidos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que los comprende; y combinacion farmaceutica. | |
CL2015003615A1 (es) | Nucleósidos sustituidos, nucleótidos y análogos de los mismos. | |
CL2011002830A1 (es) | Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c. | |
CL2014000612A1 (es) | Compuestos derivados de prolinas macrociclicas, inhibidores de las proteasas de serina del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y su uso para tratar una infeccion viral tal como la infeccion por el virus de la hepatitis c (vhc). | |
CL2007003686A1 (es) | Compuestos derivados de indol con anillo unido en las posiciones 4,5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar una infeccion viral. | |
CO6290682A2 (es) | Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c. | |
EA201270423A1 (ru) | Ингибиторы протеазы hcv | |
CO6390076A2 (es) | Inhibidores de hcv ns5a | |
CO6390077A2 (es) | Inhibidores de hacv ns5a | |
CL2008002995A1 (es) | Compuestos derivados de espiropirrolidina; composicion farmaceutica que los comprende; procedimiento de preparacion de compuestos intermediarios; y su uso para tratar la infeccion del virus de la hepatitis c y del vih. | |
CL2009002207A1 (es) | Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c. | |
CO6761335A2 (es) | Inhibidores del virus de la hepatitis c | |
CL2011002494A1 (es) | Compuestos derivados de 7-aza-di-espiro-[3.0.4.1]-decan-8-carboxamida; composición farmacéutica que los comprenden; y uso para el tratamiento de un trastorno asociado con el virus de la hepatitis c (hcv) y el virus de inmunodeficiencia humana (vih). | |
UY32721A (es) | Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados | |
UY32715A (es) | Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados | |
UY32720A (es) | Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados | |
CL2016000300A1 (es) | Métodos terapéuticos | |
BR112014013972A8 (pt) | inibidores de hcv nssa | |
CL2015003358A1 (es) | Compuestos derivados de nucleósidos 4'-azido-3'-desoxi-3'-fluoro sustituidos; composición farmacéutica que comprende a dichos compuestos y el uso de los mismos para tratar una infección del virus de la hepatitis c (hcv). | |
CL2008003045A1 (es) | Compuestos derivados de dioxolano timina fosforamidatos; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de infecciones virales, tales como el vih |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RDES | Application refused |
Effective date: 20210426 |